Comparison of efficacy of first- versus second-line adalimumab in patients with rheumatoid arthritis: Experience of the Italian biologics registries

Clinical and Experimental Rheumatology

Volumn 35, Issue 4, 2017, Pages 660-665

  Codullo, Veronica ^a   Iannone, Florenzo ^b   Sinigaglia, Luigi ^c   Favalli, Ennio Giulio ^c   Sarzi Puttini, Piercarlo ^d   Atzeni, Fabiola ^e   Ferraccioli, Gianfranco ^f   Gremese, Elisa ^f   Carletto, Antonio ^g   Giollo, Alessandro ^g   Govoni, Marcello ^h   Bergossi, Francesca ^h   Galeazzi, Mauro ⁱ   Cantarini, Luca ⁱ   Salaffi, Fausto ^j   Di Carlo, Marco ^j   Bazzani, Chiara ^k   Pellerito, Raffaele ^l   Sebastiani, Marco ^m   Ramonda, Roberta ⁿ   Lapadula, Giovanni ^b   Caporali, Roberto ^a   more..

^a UNIVERSITY OF PAVIA   (Italy)

^b UNIVERSITY OF BARI   (Italy)

^c ISTITUTO ORTOPEDICO GAETANO PINI   (Italy)

^d UNIVERSITY OF MILAN   (Italy)

^e IRCCS ISTITUTO ORTOPEDICO GALEAZZI   (Italy)

^f CATHOLIC UNIVERSITY   (Italy)

^g UNIVERSITY OF VERONA   (Italy)

^h UNIVERSITY OF FERRARA   (Italy)

ⁱ UNIVERSITY OF SIENA   (Italy)

^j UNIVERSITÀ POLITECNICA DELLE MARCHE   (Italy)

^k UNIVERSITY OF BRESCIA   (Italy)

^l MAURIZIANO HOSPITAL   (Italy)

^m UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

ⁿ UNIVERSITY OF PADOVA   (Italy)

more..

Author keywords

Adalimumab; HAQ; Remission; Rheumatoid arthritis

Indexed keywords

ADALIMUMAB; ANAKINRA; CERTOLIZUMAB PEGOL; ETANERCEPT; GOLIMUMAB; INFLIXIMAB; RITUXIMAB; TOCILIZUMAB; ANTIRHEUMATIC AGENT; CORTICOSTEROID; METHOTREXATE;

ADULT; ARTICLE; CLINICAL PRACTICE; COMPARATIVE EFFECTIVENESS; CONTROLLED STUDY; DAS28; DISEASE ACTIVITY; DISEASE CONTROL; DRUG TREATMENT FAILURE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIMARY HEALTH CARE; PRIORITY JOURNAL; REMISSION; RHEUMATOID ARTHRITIS; SECONDARY HEALTH CARE; SURVIVAL RATE; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT WITHDRAWAL; AGED; ARTHRITIS, RHEUMATOID; COMBINATION DRUG THERAPY; COMPARATIVE STUDY; ITALY; MIDDLE AGED; REGISTER; SEVERITY OF ILLNESS INDEX; TREATMENT FAILURE;

ADALIMUMAB; ADRENAL CORTEX HORMONES; ADULT; AGED; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; ITALY; MALE; METHOTREXATE; MIDDLE AGED; REGISTRIES; REMISSION INDUCTION; SEVERITY OF ILLNESS INDEX; TREATMENT FAILURE;

EID: 85028659468     PISSN: 0392856X     EISSN: 1593098X     Source Type: Journal    
DOI: None     Document Type: Article

References (18)

1. CAPORALI R, CONTI F, ALIVERNINI S et al.: Recommendations for the use of biologic therapy in rheumatoid arthritis: update from the Italian Society for Rheumatology I. Efficacy. Clin Exp Rheumatol 2011; 29 (Suppl. 66): S7-14
2. EMERY P, KAVANAUGH A, BAO Y, GANGULI A, MULANI P: Comprehensive disease control (CDC): what does achieving CDC mean for patients with rheumatoid arthritis? Ann Rheum Dis 2015; 74: 2165-74
3. CAVAGNA L, SAKETKOO LA, SCHWARTING A, CAPORALI R: Biotechnological drugs: the breakthrough in autoimmune rheumatic conditions. Biomed Res Int 2014: 481973
4. SMOLEN JS, LANDEWé R, BREEDVELD et al.: EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs. Ann Rheum Dis 2010; 69: 964-75
5. ATZENI F, SARZI-PUTTINI P, GORLA R, MARCHESONI A, CAPORALI R: Switching rheumatoid arthritis treatments: an update. Autoimmun Rev 2011; 10: 397-403
6. CAPORALI R, PALLAVICINI FB, FILIPPINI M et al.: Treatment of rheumatoid arthritis with anti-TNF-alpha agents: a reappraisal. Autoimmun Rev 2009; 8: 274-80
7. IANNONE F, GREMESE E, ATZENI F et al.: Longterm retention of tumor necrosis factor-alpha inhibitor therapy in a large Italian cohort of patients with rheumatoid arthritis from the GISEA registry: an appraisal of predictors. J Rheumatol 2012; 39: 1179-84
8. MAKINEN H, KAUTIAINEN H, HANNONEN P, SOKKA T: Is DAS28 an appropriate tool to assess remission in rheumatoid arthritis? Ann Rheum Dis 2005. 64: 1410-3
9. IANNONE F, SINIGAGLIA L, FAVALLI EG et al.: 2016. Drug survival of adalimumab in patients with rheumatoid arthritis over 10 years in the real-world settings: high rate remission together with normal function ability. Clin Rheumatol 2016; 35: 2649-56
10. SMOLEN JS, LANDEWé R, BREEDVELD FC et al.: EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update. Ann Rheum Dis 2014; 73: 492-509
11. HYRICH KL, LUNT M, WATSON KD, SYMMONS DP, SILMAN AJ, and British Society for Rheumatology Biologics, R: Outcomes after switching from one anti-tumor necrosis factor alpha agent to a second anti-tumor necrosis factor alpha agent in patients with rheumatoid arthritis: results from a large UK national cohort study. Arthritis Rheum 2007; 56: 13-20
12. FRAZIER-MIRONER A, DOUGADOS M, MARIETTE X et al.: Retention rates of adalimumab, etanercept and infliximab as first and secondline biotherapy in patients with rheumatoid arthritis in daily practice. Joint Bone Spine 2014; 81: 352-9
13. CAPORALI R, SARZI-PUTTINI P, ATZENI F et al.: Switching TNF-alpha antagonists in rheumatoid arthritis: the experience of the LORHEN registry. Autoimmun Rev 2010; 9: 465-9
14. LLOYD S, BUJKIEWICZ S, WAILOO AJ, SUTTON AJ, SCOTT D: The effectiveness of anti-TNF-alpha therapies when used sequentially in rheumatoid arthritis patients: a systematic review and meta-analysis. Rheumatology (Oxford) 2010; 49: 2313-21
15. SMOLEN JS, ALETAHA D, BIJLSMA JW et al.: Treating rheumatoid arthritis to target: recommendations of an international task force. Ann Rheum Dis 2010; 69: 631-7
16. NORTON S, FU B, SCOTT DL et al.: Health Assessment Questionnaire disability progression in early rheumatoid arthritis: systematic review and analysis of two inception cohorts. Semin Arthritis Rheum 2014; 44: 131-44
17. FEUCHTENBERGER M, KLEINERT S, SCHARBATKE EC et al.: The impact of prior biologic therapy on adalimumab response in patients with rheumatoid arthritis. Clin Exp Rheumatol 2015; 33: 321-9
18. Du PAN SM, SCHERER A, GABAY C, FINCKH A: Differential drug retention between anti-TNF agents and alternative biological agents after inadequate response to an anti-TNF agent in rheumatoid arthritis patients. Ann Rheum Dis 2012; 71: 997-9